| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Isoformononetin-d3 targets estrogen receptors (ERalpha and ERbeta) as a phytoestrogen. It also has been reported to act as an agonist of the Wnt/beta-catenin signaling pathway and to inhibit RANKL-induced osteoclastogenesis. The d3 label does not alter the binding affinity; however, the labeled version is primarily used as an analytical standard rather than for activity studies.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers for quantification throughout the drug development process. Due to its potential to alter the pharmacokinetic and metabolic characteristics of medications, deuteration has drawn attention[2].
The unlabeled isoformononetin binds to estrogen receptors in cell-free competitive binding assays using recombinant ERalpha or ERbeta proteins and a fluorescent or radioactive estradiol tracer. The IC50 for ER binding is typically in the micromolar range (phytoestrogen-level affinity). Isoformononetin-d3 is not used in these assays due to its role as an internal standard. |
| ln Vivo |
In cell-based assays (e.g., MCF-7 breast cancer cells), unlabeled isoformononetin (1-100 uM) induces estrogen-responsive gene expression (e.g., pS2, TFF1) and promotes cell proliferation at lower concentrations, while at higher concentrations it may exhibit anti-proliferative effects. It also promotes osteoblast differentiation (alkaline phosphatase activity) and inhibits osteoclast formation (TRAP staining) in primary cell cultures. Isoformononetin-d3 is used for LC-MS/MS quantification of cellular uptake.
|
| Enzyme Assay |
For analytical method development, Isoformononetin-d3 is used as an internal standard in cell-free matrices. A calibration curve is prepared by spiking known amounts of unlabeled isoformononetin into blank plasma, serum, or tissue homogenates, along with a fixed concentration of Isoformononetin-d3. Samples are extracted (e.g., liquid-liquid or SPE) and analyzed by LC-MS/MS. The peak area ratio (unlabeled/labeled) is used for quantification. No binding assay is performed with the d3 standard.
|
| Cell Assay |
Osteoblasts or MCF-7 cells are treated with unlabeled isoformononetin (0.1-100 uM) for 24-72 hours. Cell lysates or media samples are collected, and isoformononetin concentrations are measured by LC-MS/MS using Isoformononetin-d3 as the internal standard. Separately, cell viability (MTT), gene expression (qRT-PCR), and protein levels (Western blot) are assessed to determine biological activity. The d3 standard is only used in the analytical arm.
|
| Animal Protocol |
Isoformononetin-d3 can be co-administered with unlabeled isoformononetin as a tracer in animal studies (e.g., rats or mice). The compound is administered orally or intraperitoneally (10-50 mg/kg). Blood and tissues are collected at various time points (0-24 hours). Plasma and tissue homogenates are analyzed by LC-MS/MS using the d3 internal standard (which may be added post-collection, not necessarily dosed). The isotope-labeled compound ensures accurate pharmacokinetic profiling.
|
| ADME/Pharmacokinetics |
Isoformononetin has moderate oral bioavailability. After administration, it is rapidly absorbed and undergoes glucuronidation and sulfation. The terminal half-life in rodents is 1-3 hours. The deuterium label does not alter the PK properties. Isoformononetin-d3 (as an analytical standard) is stable in biological matrices under typical storage conditions (-80degC). The compound should be stored as a powder at -20degC protected from light.
|
| Toxicity/Toxicokinetics |
Isoformononetin-d3 is used in trace amounts (analytical standard) and does not contribute to toxicity. Unlabeled isoformononetin is generally recognized as safe at dietary intake levels. High doses may cause mild estrogenic effects (uterotrophic changes in animal models) or gastrointestinal disturbances. No significant acute or chronic toxicity has been reported. Standard safety precautions are sufficient. Not for human consumption.
|
| References |
|
| Additional Infomation |
Isoformononetin is a natural isoflavonoid found in red clover and other plants. It has been studied for potential benefits in osteoporosis, menopause, and cancer prevention. Isoformononetin-d3 is a research-grade stable isotope-labeled internal standard used exclusively for analytical method development (LC-MS/MS) to quantify isoformononetin in biological and food samples. It is not intended for therapeutic use. The product has high isotopic purity (≥98%).
|
| Molecular Formula |
C16H9D3O4
|
|---|---|
| Molecular Weight |
271.28
|
| Related CAS # |
Isoformononetin;486-63-5
|
| Appearance |
Off-white to light yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6862 mL | 18.4311 mL | 36.8623 mL | |
| 5 mM | 0.7372 mL | 3.6862 mL | 7.3725 mL | |
| 10 mM | 0.3686 mL | 1.8431 mL | 3.6862 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
